Glycopyrrolate 1 mg Tablets Recalled for Failed Impurity Specifications
AVKARE LLC is recalling Glycopyrrolate 1 mg tablets distributed nationwide due to failed quality specifications involving unknown impurities. The recall affects 1,237 cartons.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recalls address potential serious health consequences. Although no illnesses or injuries have been reported, unknown impurities in a pharmaceutical product represent a risk-of-harm situation.
Plain-English summary
AVKARE LLC is recalling Glycopyrrolate Tablets, USP, 1 mg in unit dose cartons (lot numbers 43313 and 43342, expiring 12/2023) because the product failed quality specifications related to unknown impurities. The affected product was distributed nationwide in the United States.
The recall is based on failed quality specifications. Patients who have received glycopyrrolate from the recalled lot numbers should consult their healthcare provider or pharmacist.
Healthcare providers and pharmacists with the affected product should verify lot numbers and quarantine any affected cartons.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- AVKARE LLC
- Category
- Drug
- Hazard
- unknown-impurities
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot#: 43313
- 43342
- Exp 12/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
FDA (Drugs) · 2023-06-14
- ModerateGlycopyrrolate injection recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighGlycopyrrolate Injection, USP recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighPrescription Glycopyrrolate Injection Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01